Literature DB >> 31812658

Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men.

Monika Sarkar1, Katherine Yates2, Ayako Suzuki3, Joel Lavine4, Ryan Gill5, Toni Ziegler6, Norah Terrault7, Sandeep Dhindsa8.   

Abstract

With rising prevalence of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease. One-third of obese or diabetic men have subnormal free and bioavailable testosterone concentrations.1 Several studies have further shown low testosterone to be associated with imaging-confirmed NAFLD in men,2 although it is unknown whether low testosterone confers increased risk of more clinically relevant manifestations of NAFLD, including nonalcoholic steatohepatitis (NASH) and NASH fibrosis. We therefore aimed to evaluate the association of testosterone with histologic features of NAFLD among a representative cohort of men from the multicenter NASH Clinical Research Network (NASH CRN).
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31812658      PMCID: PMC7272262          DOI: 10.1016/j.cgh.2019.11.053

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  A critical evaluation of simple methods for the estimation of free testosterone in serum.

Authors:  A Vermeulen; L Verdonck; J M Kaufman
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

2.  Identification of late-onset hypogonadism in middle-aged and elderly men.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

3.  Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.

Authors:  D Kapoor; E Goodwin; K S Channer; T H Jones
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

Review 4.  Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Authors:  Veeravich Jaruvongvanich; Anawin Sanguankeo; Tanawan Riangwiwat; Sikarin Upala
Journal:  Ann Hepatol       Date:  2017 May - Jun       Impact factor: 2.400

5.  Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.

Authors:  Sandeep Dhindsa; Husam Ghanim; Manav Batra; Nitesh D Kuhadiya; Sanaa Abuaysheh; Sartaj Sandhu; Kelly Green; Antoine Makdissi; Jeanne Hejna; Ajay Chaudhuri; Mark Punyanitya; Paresh Dandona
Journal:  Diabetes Care       Date:  2015-11-29       Impact factor: 19.112

6.  High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men.

Authors:  Yuya Fujihara; Nobuya Hamanoue; Hiromi Yano; Makito Tanabe; Yuko Akehi; Takashi Nomiyama; Toshihiko Yanase
Journal:  Endocr J       Date:  2019-05-09       Impact factor: 2.349

Review 7.  Hypogonadotropic Hypogonadism in Men With Diabesity.

Authors:  Sandeep Dhindsa; Husam Ghanim; Manav Batra; Paresh Dandona
Journal:  Diabetes Care       Date:  2018-07       Impact factor: 19.112

8.  Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife.

Authors:  Monika Sarkar; Lisa B VanWagner; James G Terry; J Jeffrey Carr; Mary Rinella; Pamela J Schreiner; Cora E Lewis; Norah Terrault
Journal:  Am J Gastroenterol       Date:  2019-05       Impact factor: 12.045

  8 in total
  9 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

2.  Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations.

Authors:  Ross Apostolov; Emily Gianatti; Darren Wong; Numan Kutaiba; Paul Gow; Mathis Grossmann; Marie Sinclair
Journal:  World J Hepatol       Date:  2022-04-27

3.  Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis.

Authors:  Man-Qiu Mo; Zi-Chun Huang; Zhen-Hua Yang; Yun-Hua Liao; Ning Xia; Ling Pan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-06-24       Impact factor: 4.435

Review 4.  Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.

Authors:  Amedeo Lonardo; Ayako Suzuki
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

5.  Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study.

Authors:  Ya-Ping Huang; Shi Zhang; Minying Zhang; Yi Wang; Wen-Hong Wang; Jing Li; Chunjun Li; Jing-Na Lin
Journal:  BMJ Open       Date:  2021-12-15       Impact factor: 2.692

6.  Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis.

Authors:  Xiaofang Zhang; Yuchan Mou; Elif Aribas; Masoud Amiri; Jana Nano; Wichor M Bramer; Maryam Kavousi; Robert J de Knegt; Eralda Asllanaj; Mohsen Ghanbari
Journal:  Genes (Basel)       Date:  2022-05-27       Impact factor: 4.141

Review 7.  Growth hormone deficiency and NAFLD: An overlooked and underrecognized link.

Authors:  Iliana Doycheva; Dana Erickson; Kymberly D Watt
Journal:  Hepatol Commun       Date:  2022-06-28

8.  Low Serum Total Testosterone Is Associated with Non-Alcoholic Fatty Liver Disease in Men but Not in Women with Type 2 Diabetes Mellitus.

Authors:  Xinxin Zhang; Jinfeng Xiao; Qi Liu; Yuanyuan Ye; Weihong Guo; Jingqiu Cui; Qing He; Wenli Feng; Ming Liu
Journal:  Int J Endocrinol       Date:  2022-08-27       Impact factor: 2.803

9.  Hypogonadism and liver fibrosis in HIV-infected patients.

Authors:  E Quiros-Roldan; T Porcelli; L C Pezzaioli; M Degli Antoni; S Paghera; M Properzi; E Focà; C Carriero; F Castelli; A Ferlin
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.